If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.
We set cookies so you can manage your account and navigate the site, and to remember your cookie preferences so that you don't keep getting this message. To accept cookies, just keep browsing, otherwise use the links on the right to adjust your cookie settings or find out more.
Biogen Idec is suspending the marketing of its multiple-sclerosis drug Tysabri (natalizumab), following one confirmed and fatal case, and another confirmed case, of progressive multifocal leukoencephalopathy (PML) in patients taking the monoclonal-antibody drug